Featured Publications
Oropharyngeal Cancer Early Outcomes and Challenges During the COVID-19 Pandemic
Kang J, Wu Y, Rybkin A, Yu Y, Chen L, Zakeri K, McBride S, Riaz N, Tsai C, Gelblum D, Wong R, Sherman E, Pfister D, Lee N. Oropharyngeal Cancer Early Outcomes and Challenges During the COVID-19 Pandemic. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e412. PMCID: PMC8536212, DOI: 10.1016/j.ijrobp.2021.07.1185.Peer-Reviewed Original ResearchDefinitive radiation therapyCOVID cohortRadiation therapyMore patientsAdvanced diseaseMonth outcomesPC cohortNew patientsCurative-intent radiation therapyGrade 3 dysphagiaOropharyngeal cancer outcomesCancer-specific survivalSupportive care needsKaplan-Meier methodLong-term outcomesDiagnosis/treatmentCOVID-19 pandemicMATERIAL/METHODSPerson consultsRT startClinicopathologic factorsOPC patientsHistorical cohortMedian timeEarly outcomes
2022
Prognosis of P16 and HPV Discordant Oropharyngeal Cancers: Natural Language Processing to Extract Data from Free-Text Pathology Reports
Shin E, Cartano O, Lee N, Kang J. Prognosis of P16 and HPV Discordant Oropharyngeal Cancers: Natural Language Processing to Extract Data from Free-Text Pathology Reports. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e322. DOI: 10.1016/j.ijrobp.2022.07.1391.Peer-Reviewed Original ResearchCancer-specific survivalHuman papillomavirus resultsOropharyngeal cancerHuman papillomavirusIn situ hybridizationP16 immunohistochemistryClinical trial eligibilityOverall survivalDiscordant tumorsPathology reportsTrial eligibilityFollow-upHuman papillomavirus in situ hybridizationEstimate cancer-specific survivalHuman papillomavirus testingTreatment de-escalationMedian follow-upDetect human papillomavirusKaplan-Meier methodSeries of patientsMinority of patientsExcellent prognosisClinical outcomesClinical managementDivergent prognoses
2018
First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology
Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. European Urology Oncology 2018, 1: 378-385. PMID: 31158076, DOI: 10.1016/j.euo.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedFollow-Up StudiesHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualPostoperative PeriodPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSalvage TherapySurvival AnalysisConceptsBone metastasis-free survivalProstate cancer-specific survivalUltrasensitive prostate specific antigenOverall survivalBiochemical relapseProstate-specific antigenRadical prostatectomyMultivariate analysisProstate-specific antigen levelImmediate adjuvant therapyOccult prostate cancerOccult systemic diseaseCancer-specific survivalEarly salvage radiotherapyHigh-risk diseaseKaplan-Meier methodTraditional risk factorsMetastasis-free survivalPrediction of outcomeProstate cancer pathologyAdjuvant therapySalvage radiotherapyHormone therapyIndependent predictorsStudy endpoint